Literature DB >> 22920611

Infection risk for primary and revision instrumented lumbar spine fusion in the Medicare population.

Steven M Kurtz1, Edmund Lau, Kevin L Ong, Leah Carreon, Heather Watson, Todd Albert, Steven Glassman.   

Abstract

OBJECT: This retrospective analysis of Medicare administrative data was performed to evaluate the risk of infection following instrumented lumbar fusion over a 10-year follow-up period in the Medicare population. Although infection can be a devastating complication, due to its rarity it is difficult to characterize infection risk except in large patient populations.
METHODS: Using ICD-9-CM and CPT4 procedure codes, the Medicare 5% analytical research files for inpatient, outpatient, and physician carrier claims were checked to identify patients who were treated between 1997 and 2009 with lumbar spine fusion in which cages or posterior instrumentation were used. Patients younger than 65 years old were excluded. Patients were followed continuously by using the matching denominator file until they withdrew from Medicare or died. The authors identified 15,069 patients with primary fusion procedures and 605 with revision of instrumented lumbar fusion. Infections were identified by the related ICD-9 codes (998.59 or 996.67) after fusion. Kaplan-Meier survival analysis and Cox regression were performed to determine adjusted infection risk for each type of spine procedure (primary vs revision) and surgical approach (anterior, posterior, combined anteroposterior), accounting for patient (for example, age, sex, comorbidities/Charlson Comorbidity Index [CCI], and state buy-in) and hospital (census region) characteristics.
RESULTS: At 10 years, the overall infection incidence, including superficial and deep infections, was 8.5% in primary procedures and 12.2% in revisions. Among the factors considered, infection risk within 10 years was most influenced by comorbidities: for a CCI of 5 versus 0, the adjusted hazard ratio (AHR) was 2.48 (95% CI 1.93-3.19, p < 0.001); for ≥ 9 versus 2-3 fused vertebrae, the AHR was 2.39 (95% CI 1.20-4.76, p < 0.001); for revision versus primary fusion procedures, the AHR was 1.66 (95% CI 1.28-2.15, p < 0.001). Other significant predictors of 10-year infection risk included diagnosis of obesity (p < 0.001); state buy-in--a proxy for socioeconomic status (p = 0.02); age (p = 0.003); surgical approach (p = 0.03); census region (p = 0.02); and the year of the index procedure (p = 0.03).
CONCLUSIONS: Patient comorbidities were the greatest predictor of infection risk for the Medicare population. The high incidence of infection following instrumented fusion warrants increased focus on infection risk mitigation, especially for patients with comorbid conditions.

Entities:  

Mesh:

Year:  2012        PMID: 22920611     DOI: 10.3171/2012.7.SPINE12203

Source DB:  PubMed          Journal:  J Neurosurg Spine        ISSN: 1547-5646


  38 in total

1.  Higher Charlson Comorbidity Index Scores are associated with readmission after orthopaedic surgery.

Authors:  Timothy Voskuijl; Michiel Hageman; David Ring
Journal:  Clin Orthop Relat Res       Date:  2013-11-26       Impact factor: 4.176

2.  Bacterial adhesion characteristics on implant materials for intervertebral cages: titanium or PEEK for spinal infections?

Authors:  Samira Weisselberg; Sven Oliver Eicker; Theresa Krätzig; Klaus Christian Mende; Malte Mohme; Simon von Kroge; Martin Stangenberg; Marc Dreimann; Manfred Westphal
Journal:  Eur Spine J       Date:  2021-01-09       Impact factor: 3.134

3.  [Risk factors for surgical site infection following posterior lumbar intervertebral fusion].

Authors:  Chaohui Sang; Hailong Ren; Zhandong Meng; Jianming Jiang
Journal:  Nan Fang Yi Ke Da Xue Xue Bao       Date:  2018-07-30

4.  Risk factors for deep surgical site infection following posterior instrumented fusion for degenerative diseases in the thoracic and/or lumbar spine: a multicenter, observational cohort study of 2913 consecutive cases.

Authors:  Satoshi Ogihara; Takashi Yamazaki; Michio Shiibashi; Hirotaka Chikuda; Toru Maruyama; Kota Miyoshi; Hirohiko Inanami; Yasushi Oshima; Seiichi Azuma; Naohiro Kawamura; Kiyofumi Yamakawa; Nobuhiro Hara; Jiro Morii; Rentaro Okazaki; Yujiro Takeshita; Sakae Tanaka; Kazuo Saita
Journal:  Eur Spine J       Date:  2021-01-29       Impact factor: 3.134

5.  What are the risk factors for surgical site infection after spinal fusion? A meta-analysis.

Authors:  Sebastien Pesenti; Tejbir Pannu; Jessica Andres-Bergos; Renaud Lafage; Justin S Smith; Steve Glassman; Marinus de Kleuver; Ferran Pellise; Frank Schwab; Virginie Lafage
Journal:  Eur Spine J       Date:  2018-08-20       Impact factor: 3.134

6.  Acoustic Parameters for Optimal Ultrasound-Triggered Release from Novel Spinal Hardware Devices.

Authors:  Lauren J Delaney; Cemile Basgul; Daniel W MacDonald; Keith Fitzgerald; Noreen J Hickok; Steven M Kurtz; Flemming Forsberg
Journal:  Ultrasound Med Biol       Date:  2019-11-13       Impact factor: 2.998

Review 7.  [Infections after reconstructive spinal interventions : How do I deal with them?]

Authors:  Burkhard Lehner; Michael Akbar; Nicholas A Beckmann
Journal:  Orthopade       Date:  2018-04       Impact factor: 1.087

8.  Incidence of surgical site infection after spine surgery: what is the impact of the definition of infection?

Authors:  Sjoerd P F T Nota; Yvonne Braun; David Ring; Joseph H Schwab
Journal:  Clin Orthop Relat Res       Date:  2015-05       Impact factor: 4.176

9.  Preventing surgical site infections: a randomized, open-label trial of nasal mupirocin ointment and nasal povidone-iodine solution.

Authors:  Michael Phillips; Andrew Rosenberg; Bo Shopsin; Germaine Cuff; Faith Skeete; Alycia Foti; Kandy Kraemer; Kenneth Inglima; Robert Press; Joseph Bosco
Journal:  Infect Control Hosp Epidemiol       Date:  2014-05-21       Impact factor: 3.254

10.  The use of local vancomycin powder in degenerative spine surgery.

Authors:  Josh E Schroeder; Fredrico P Girardi; Harvinder Sandhu; Joseph Weinstein; Frank P Cammisa; Andrew Sama
Journal:  Eur Spine J       Date:  2015-08-07       Impact factor: 3.134

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.